oncolytic viral therapy
INGN 007, in preclinical studies, is a replication-competent viral therapy, which is also called an oncolytic virus, in which viruses bind directly to cancer cells, replicate in those cells, and cause those cancer cells to die. Testing in animal models indicates INGN 007 over-expresses a molecule that allows the vector to saturate the entire tumor. This testing has demonstrated that INGN 007 has a favorable safety profile and significantly inhibits tumor growth.
| Cancer Indication | Status |
| Various (solid tumors) | Pre-clinical |
** We hold the worldwide commercial rights to the product candidates related to each of these programs.
